Unknown PHASE1 INTERVENTIONAL 1-arm NCT03114670

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Donor-derived Anti-CD123 Chimeric Antigen Receptors Modified T Cells for Recurred Acute Myeloid Leukaemia After Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences

Conditions Adult Acute Myeloid Leukemia

Interventions CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells

Updated 8 times since 2017 Last updated: Jun 13, 2017 Started: Mar 25, 2017 Primary completion: Mar 18, 2019 Completion: Mar 18, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Adult Acute Myeloid Leukemia, this trial is ongoing. The trial is conducted by Affiliated Hospital to Academy of Military Medical Sciences and has accumulated 8 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Recruiting PHASE1
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE1
May 2017 — Jun 2017 [monthly]

Recruiting PHASE1

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affiliated Hospital to Academy of Military Medical Sciences

Data source: Affiliated Hospital to Academy of Military Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China